Treatment of cancer using hypoxia activated prodrugs

US8946275B2 · kind B2 · utility

Assignee

• Threshold Pharmaceuticals, Inc. · US

Inventors

• John G. Curd · Hillsborough, US
• Stewart Kroll · Oakland, US
• Mark Matteucci · Burlingame, US
• Charles Hart · South San Francisco, US
• Jian-Xin Duan · South San Francisco, US

Key dates

• Filing date: Oct 21, 2009
• Grant date: Feb 3, 2015
• Expiry date: Mar 23, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.